Related Experiment Video
Updated: Jun 22, 2025
09:10
Intestinal Epithelial Regeneration in Response to Ionizing Irradiation
Published on: July 27, 2022
2.2K
Toll-like Receptor Agonist CBLB502 Protects Against Radiation-induced Intestinal Injury in Mice
Qiong Wang1,2, Junzhao Duan2, Jian Hong3
1School of Basic Medical Sciences, Anhui Medical University, Hefei, P.R. China.
In Vivo (Athens, Greece)
|June 27, 2024
Summary
CBLB502, a Toll-like receptor 5 agonist, protects against ionizing radiation (IR) induced intestinal injury in mice. It works by reversing IR-induced gene expression and regulating immune and metabolic pathways.
Area of Science:
- Radiation biology
- Immunology
- Molecular mechanisms
Background:
- The small intestine is highly susceptible to ionizing radiation (IR) damage.
- Current protective strategies against IR-induced intestinal injury are limited.
- CBLB502, a Toll-like receptor 5 (TLR5) agonist, shows potential radioprotective effects.
Purpose of the Study:
- To elucidate the mechanisms of IR-induced intestinal injury.
- To investigate the protective effects of CBLB502 against IR-induced intestinal injury.
- To understand the molecular mechanisms underlying CBLB502's radioprotection.
Main Methods:
- Mice were treated with CBLB502 prior to varying doses of IR.
- Survival rates, body weight, hemograms, and histopathology were analyzed.
- RNA-sequencing was employed to analyze gene expression patterns.
Main Results:
- CBLB502 significantly reduced IR-induced intestinal injury.
- IR induced distinct gene expression patterns based on dose and duration.
- CBLB502 reversed IR-induced gene expression and modulated immune and metabolic pathways.
Conclusions:
- This study provides preliminary insights into the regulatory mechanisms of IR-induced intestinal injury.
- The findings suggest CBLB502 protects against intestinal injury by modulating gene expression and key biological pathways.
- This research lays the groundwork for identifying specific genes and molecular pathways involved in radioprotection.
